Donafenib plus immunotherapy and local therapy for liver cancer after prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of the targeted drug donafenib, immunotherapy, and local treatments (like chemo delivered directly to the liver) for people with liver cancer that cannot be removed by surgery and has stopped responding to previous treatments. The goal is to see if this new combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have liver cancer (hepatocellular carcinoma) that cannot be removed by surgery.
- Your cancer has grown or worsened after previous targeted therapy (not donafenib) with or without immunotherapy or local treatments.
- You have at least one tumor that can be measured on scans.
- Your liver function is good to moderate (Child-Pugh class A or B).
- If you have hepatitis B or C, your virus levels must be controlled with proper treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for liver cancer that cannot be removed by surgery: blocking blood supply to the tumor (TACE), precise radiation (SBRT), and an immunotherapy that helps your immune system fight the cancer. It also uses a targeted medication called Donafenib. The goal is to see if this triple therapy works better than current options.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This study looks at combining donafenib (a targeted therapy) with an immunotherapy drug (PD-1/L1 inhibitor) and either TACE or HAIC (two types of minimally invasive treatments for liver tumors) as a first treatment for people with liver cancer that cannot be removed by surgery. It aims to see how well this combination works and how safe it is.
This trial tests a new targeted therapy called donafenib for patients with advanced hepatocellular carcinoma (liver cancer) that cannot be surgically removed. The drug may help slow or shrink the cancer in patients who haven't received systemic chemotherapy before.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.